Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32 CHF | -2.74% | -3.90% | -35.87% |
04-23 | Xlife Sciences Posts Higher FY23 Profit; Revenue Falls | MT |
02-29 | Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 800K 869K 69.67M | Sales 2025 * | - | Capitalization | 183M 198M 15.89B |
---|---|---|---|---|---|
Net income 2024 * | -4M -4.35M -348M | Net income 2025 * | - | EV / Sales 2024 * | 310 x |
Net Debt 2024 * | 65.2M 70.84M 5.68B | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-48.5
x | P/E ratio 2025 * |
-
| Employees | 17 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 49.77% |
1 day | -2.74% | ||
1 week | -3.90% | ||
Current month | -28.89% | ||
1 month | -28.89% | ||
3 months | -34.02% | ||
6 months | -17.74% | ||
Current year | -35.87% |
Managers | Title | Age | Since |
---|---|---|---|
Oliver Baumann
CEO | Chief Executive Officer | - | 30/06/19 |
Carl von Halem
DFI | Director of Finance/CFO | - | 30/11/21 |
Alexander Zink
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Christian Faber
CMP | Compliance Officer | - | 11/09/19 |
Mark Müller
BRD | Director/Board Member | - | 24/10/18 |
Oliver Baumann
CEO | Chief Executive Officer | - | 30/06/19 |
Date | Price | Change | Volume |
---|---|---|---|
30/04/24 | 32 | -2.74% | 7,267 |
29/04/24 | 32.9 | -4.08% | 4,213 |
26/04/24 | 34.3 | -.--% | 4,112 |
25/04/24 | 34.3 | -0.29% | 2,751 |
24/04/24 | 34.4 | -1.43% | 4,517 |
Delayed Quote Swiss Exchange, April 30, 2024 at 04:31 pm
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-35.87% | 206M | |
+0.17% | 42.86B | |
+10.92% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.23% | 25.15B | |
-24.79% | 18.63B | |
+26.69% | 12.37B | |
-3.13% | 11.92B | |
+6.57% | 11.21B |
- Stock Market
- Equities
- XLS Stock